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Abstract
Introduction Diabetes mellitus (DM) is one of the most common
chronic co-morbid medical conditions in the USA and is
frequently present in patients with sepsis. Previous studies
reported that people with DM and severe sepsis are less likely
to develop acute lung injury (ALI). We sought to determine
whether organ dysfunction differed between people with and
without DM and sepsis.
Methods Using the National Hospital Discharge Survey US,
sepsis cases from 1979 to 2003 were integrated with DM
prevalence from the Centers for Disease Control and Prevention
(CDC) Diabetes Surveillance System.
Results During the study period 930 million acute-care
hospitalisations and 14.3 million people with DM were
identified. Sepsis occurred in 12.5 million hospitalisations and
DM was present in 17% of patients with sepsis. In the
population, acute respiratory failure was the most common
organ dysfunction (13%) followed by acute renal failure (6%).
People with DM were less likely to develop acute respiratory
failure (9% vs. 14%, p < 0.05) and more likely to develop acute
renal failure (13% vs. 7%, p < 0.05). Of people with DM and
sepsis, 27% had a respiratory source of infection compared
with 34% in people with no DM (p < 0.05). Among patients with
a pulmonary source of sepsis, 16% of those with DM and 23%
of those with no DM developed acute respiratory failure (p <
0.05); in non-pulmonary sepsis acute respiratory failure
occurred in 6% of people with DM and 10% in those with no DM
(p < 0.05).
Conclusions In sepsis, people with diabetes are less likely to
develop acute respiratory failure, irrespective of source of
infection. Future studies should determine the relationship of
these findings to reduced risk of ALI in people with DM and
causative mechanisms.
Introduction
Sepsis is a common disease that continues to increase in inci-
dence in the USA [1]. Severe sepsis, sepsis associated with
acute organ system dysfunction, is frequently encountered in
the intensive care unit (ICU) population and is associated with
a high morbidity and mortality [2]. Of the disorders commonly
associated with acute lung injury (ALI), sepsis carries the high-
est risk of progression at about 40% [3,4]. Specific risk fac-
tors, including age and chronic co-morbid medical conditions,
such as chronic liver disease, HIV infection and cancer, have
been identified that predispose patients to sepsis or severe
sepsis [5-9]. The ability of chronic co-morbid medical condi-
tions, such as diabetes mellitus (DM), to influence the risk of
sepsis or sepsis-related organ dysfunction remains unclear.
ALI: acute lung injury; ARDS: acute respiratory distress syndrome; CDC: Centers for Disease Control and Prevention; CNS: central nervous system; 
DM: diabetes mellitus; GU: genitourinary; ICD-9-CM: Clinical Modification of the International Classification of Diseases, 9th Revision; IL: interleukin; 
NF: nuclear factor; NHDS: National Hospital Discharge Survey; RSE: relative standard error; TNF: tumour necrosis factor; TZD: thiazolidinediones.Critical Care    Vol 13 No 1    Esper et al.
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DM is one of the most common diseases in the USA, with sta-
tistics from the Centers for Disease Control and Prevention
(CDC) reporting that in 2005 almost 21 million people in the
USA (7% of the population) have DM. The prevalence of DM
is rising [10] and from 2002 to 2005, 2.6 million individuals
have been newly diagnosed with DM. Patients with DM are at
increased risk of developing infections and are frequently part
of both epidemiological studies and clinical trials in critically ill
patients. For example, two studies have suggested that
patients with DM and septic shock are less likely to develop
ALI [11,12]. This may be due to differences in the inflammatory
response between people with and without DM. However, at
this time the aetiology for this association remains unclear, and
may represent differential risk for organ dysfunction as a
whole. In order to further understand differences between crit-
ically ill patients with and without DM, we sought to identify dif-
ferences in organ dysfunction between patients with and
without DM and sepsis. Accurate identification of populations
at risk for acute organ dysfunction is crucial to improve our
understanding of the mechanisms involved and to develop
novel therapies for these patients.
Materials and methods
Dataset
The National Center for Health Statistics has conducted the
National Hospital Discharge Survey (NHDS) continuously
since 1965 [13]. Since 1979, the NHDS has conformed to
the guidelines of the Uniform Hospital Discharge Data Set for
consistency of reporting in records. The NHDS is composed
of a sample of all nonfederal acute care hospitals in the USA,
including about 500 hospitals. Discharge records from inpa-
tients are surveyed from each hospital, representing about 1%
of all hospitalisations in the USA. The database includes
patient-specific information such as age, sex, self-reported
racial category, seven diagnostic and four procedural codes
(from the Clinical Modification of the International Classifica-
tion of Diseases, 9th Revision (ICD-9-CM)), sources of pay-
ment and discharge disposition. DM prevalence from 1979 to
2003 was obtained from the CDC Diabetes Surveillance Sys-
tem which collects, analyses and disseminates data on DM
and its complications [14].
Identification of cases
Cases of patients with sepsis were identified from discharge
records in the NHDS during the 25-year period from 1979 to
2003 that included an ICD-9-CM code for sepsis as previ-
ously validated [1,15]: 038.x (septicaemia), 790.7 (bacterae-
mia), 117.9 (disseminated fungal infection), 112.5 (systemic
candidiasis) and 112.81 (disseminated fungal endocarditis).
Type of infection refers to the causative organism for sepsis;
source of infection refers to the anatomical site of infection.
Type and source of infection, DM and acute organ dysfunction
were identified using ICD-9 groupings, as previously pub-
lished. Source of infection: Respiratory 010.0 to 011.9, geni-
tourinary 098.17, gastrointestinal 001.9 to 009.9, bone/joint
730.9, skin/soft tissue 003.24, central nervous system (CNS)
013, cardiovascular 036.45 to 036.43; DM 250.x; organ dys-
function: respiratory 96.7× to ventilator management, 518.x to
acute respiratory failure, acute respiratory distress syndrome
(ARDS), ARDS after shock or trauma, cardiovascular 458.x,
785.5, renal 39.95, 580.x, 584.x, hepatic 570, haematological
287.4, 286.9, metabolic 276.2, CNS 780.01, 780.09, 348.x.
Chronic co-morbid medical conditions were also cumulatively
quantified by an established co-morbidity index (Charlson-
Deyo score) [16-18]. Other outcome variables such as mortal-
ity, length of stay and discharge status were collected. All data
collected represent data available during hospitalisation,
therefore long-term outcome data is not available. This project
was exempt from the requirement for informed consent
according to federal regulations of human subjects protection
45 CFR § 46.101(b). The Emory Institutional Review Board
approved the study as exempt from the requirement for
consent.
Statistical analysis
All estimates are presented according to accepted guidelines
for the accuracy of NHDS data, restricting use to absolute,
unweighted samples of more than 60 patients with relative
standard error (RSE) measures of less than 30% for data anal-
ysis. The RSE was calculated as a first-order Taylor-series
approximation, as outlined in the RSE tables of the 2000
NHDS documentation. The standard error was calculated by
multiplying the RSE by the estimated incidence or mortality
rate, and 95% confidence intervals (CI) were calculated from
these standard errors with the use of Excel software (Microsoft
Corporation, Redmond, Washington). Data for continuous var-
iables were compared by analysis of variance and data for cat-
egorical variables were compared by the chi-squared test, with
the use of SAS software (SAS 9.1 for Windows; SAS Insti-
tute, Cary, North Carolina). When stated race was missing for
a given observation (ranging from 1 to 20% for any given year),
these persons were excluded from the calculations of race
specific rates but were included in all other calculations of
rates. An a priori stratified analysis between pulmonary and
non-pulmonary sources of sepsis was conducted to differenti-
ate the risk of acute respiratory failure in patients with a pulmo-
nary source of infection. Differences were considered
significant when the 95% CIs did not overlap and/or when
two-sided p-values were less than 0.05.
Results
Using the NHDS, from the years 1979 to 2003, there were
12.5 million cases of sepsis identified and DM was present in
17% (2,070,459) of the cases. Based on the CDC Diabetes
Surveillance System, the number of persons with DM in the
USA increased from 5,762,000 persons in 1980 to
14,275,000 in 2003. Among general hospitalised patients the
frequency of DM increased from 5.2% in 1979 to 13.3% in
2003. The frequency of DM among septic patients increasedAvailable online http://ccforum.com/content/13/1/R18
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from 11% (17,249 cases) in 1979 to 18% (122,824 cases) in
2003.
Demographics and causes of sepsis
Demographic data for populations with and without DM and
sepsis are shown in Table 1. Forty-three percent (892,230) of
people with DM and sepsis were male and 57% (1,178,229)
were female (p < 0.001). Among the patients with sepsis and
DM, 64% were white, 17% black and 5% other race. The
mean number of co-morbidities was greater in people with DM
and sepsis (2.07) compared with people with sepsis and no
DM (0.88, p < 0.0001).
Figure 1 represents the sources of infections in patients with
and without DM and sepsis. A respiratory source of infection
was present in 27% of patients with DM and sepsis compared
with 34% in patients with no DM (p < 0.05). People with DM
had an increased frequency of genitourinary (GU; 28% vs.
22%), skin soft tissue (4% vs. 2%) and bone (3% vs. 2%)
infections in comparison to people with no DM (p < 0.05).
Organ dysfunction
In the overall population of patients with sepsis, 13% devel-
oped acute respiratory failure, 8% acute renal failure, 4% car-
diovascular failure and 6% developed other organ
dysfunctions. People with DM and sepsis were more likely to
develop acute renal failure compared with people with no DM
(13% vs. 7%, p < 0.05) and are less likely to develop acute
respiratory failure (9% vs. 14%, p < 0.05). There were no dif-
ferences in the occurrence of other organ dysfunctions
between the two groups or in the overall mean number of
organ dysfunctions.
To account for differences between people with and without
DM, the frequency and type of organ dysfunction was exam-
ined within strata of infection sources. Among patients with
respiratory source of sepsis, 16% of those with DM developed
acute respiratory failure compared with 23% in people with no
DM (p < 0.05). Among patients with a non-pulmonary source
of sepsis, those with DM were still less likely to develop acute
respiratory failure when compared with those with no DM (6%
vs. 10%, p < 0.05). People with DM and sepsis were more
Table 1
Demographic characteristics of patients with sepsis from 1979 to 2003.
Patients with diabetes Patients with no diabetes
Number of patients (n) 2,070,459 10,430,000
Age (mean, years) 68 59
Race
Caucasian 64% 67%
Black 17% 14%
Other 5% 4%
Unknown 14% 15%
Gender
Male (%) 43% 49%
Female (%) 57% 51%
Pathogens (%)
Gram negatives 25% 22%
Gram positives 29% 28%
Anaerobic 1% 1%
Fungal 2.4% 2.2%
Unknown 43% 49%
Number of co-morbidities (mean) 2.07 0.88
Number of dysfunctional organ systems (mean) 0.36 0.41
Mean hospital length of stay (days) 13 14
Case fatality (%) 18.5% 20.6%Critical Care    Vol 13 No 1    Esper et al.
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likely to develop acute renal failure than those with no DM irre-
spective of the source of infection (10% vs. 6% for pulmonary
sepsis, 14% vs. 8% for non-pulmonary sepsis; both p < 0.05).
When a GU source of infection was compared with a non-GU
source of infection, people with DM and sepsis were still more
likely to develop acute renal failure than those with no DM.
Among people with DM and sepsis, 46% with a non-GU
source of infection developed acute renal failure, compared
with 44% with a GU source of infection. The only other signif-
icant difference in organ dysfunction was observed in non-pul-
monary sepsis: haematological failure occurred in 1.6% of
patients with DM and in 3.1% of those with no DM (p < 0.05)
(Figures 2 and 3).
Outcomes
Among patients with sepsis, the case-fatality rate was lower
for those with DM at 18.5% versus 20.6% in those with no DM
(p < 0.05). No other significant differences were found in case
fatality with respect to source of infection except for GU sep-
sis at 9% for those with DM vs. 12% in patients with no DM (p
< 0.05). People with DM and sepsis who developed acute res-
piratory failure had a case fatality rate of 52% versus 48% in
those with no DM (p = NS).
Discharge status
Over the study period, the hospital length of stay for people
with DM was 12.8 days versus 14.1 days in those with no DM
(p < 0.001). Discharge status during the study period was dif-
ferent between patients with and without diabetes: patients
with no DM were more likely to be discharged home (65% vs.
58%, respectively, p < 0.05) whereas patients with DM were
more likely to be discharged to an outside health care facility
(32% vs. 28%, respectively, p < 0.05).
Discussion
The current epidemiological study allows us to further charac-
terise the impact of DM on the development of organ dysfunc-
tion among patients with sepsis. When compared with
patients with severe sepsis and no DM, people with DM are
less likely to develop acute respiratory failure. The lower risk of
acute respiratory failure among patients with severe sepsis
and DM was irrespective of whether the primary source of
infection was pulmonary or non-pulmonary. With respect to
other organ dysfunctions, people with DM were more likely to
develop acute renal failure. The presence of a GU source of
infection did not affect the development of acute renal failure
among those with DM. The decrease in the frequency of res-
piratory failure in people with DM was associated with a signif-
icant difference in case fatality.
These data are consistent with previous observations made by
our group in a study evaluating the impact of DM on the devel-
opment of ARDS in patients with septic shock [11]. In that pro-
spective multi-centre ICU study, 28% of the patients with
septic shock had a history of DM. Patients in the ICU with no
DM were more likely to have pneumonia, urinary tract and
abdominal infections. Only 25% of patients with DM devel-
oped ARDS compared with 47% of those with no DM (p =
0.03, relative risk = 0.53, 95% CI = 0.28 to 0.98). In a multi-
variable model, the protective association between DM and
the development of ARDS remained significant. Our novel
observation was confirmed in another prospective cohort
study of 688 heterogeneous patients in the ICU [12]. After
multivariate adjustment, DM was again associated with a
decreased risk of ARDS, with a similar odds ratio of 0.58
(95% CI = 0.36 to 0.92). In agreement with the current study,
the above data suggest that people with DM and a variety of
Figure 1
Frequency of sepsis cases Frequency of sepsis cases. Frequency of sepsis cases among patients 
with diabetes mellitus (DM) and those with no diabetes mellitus (non-
DM) with a source of infection identified. 
CV = cardiovascular; GI = gastrointestinal; GU = genitourinal; Resp = 
respiratory; SST = skin and soft tissue. * p < 0.05.
Figure 2
Frequency of acute organ dysfunction Frequency of acute organ dysfunction. Frequency of acute organ dys-
function in patients with diabetes mellitus (DM) and those with no dia-
betes mellitus (non-DM) with a respiratory source of sepsis. 
CV = cardiovascular; Heme = haematological; Resp = respiratory. * p 
< 0.05.Available online http://ccforum.com/content/13/1/R18
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other conditions are less likely to develop both acute respira-
tory failure and ARDS.
Our present study has limitations related to the use of hospital
administrative data. Although the use of ICD-9 codes to iden-
tify specific medical conditions is not ideal, it has been vali-
dated for sepsis as having a positive predictive value of 88.9%
and a sensitivity of 87.7% [1,15]. Individual patient-level data,
such as medications, haemoglobin A1C levels and glucose lev-
els would be difficult to obtain from such data sets. The study
is further limited by the lack of data on severity of organ dys-
function, which may have implications on other outcomes. Dis-
crimination between patients with type 1 and type 2 DM may
also provide clues to mechanisms for differential organ dys-
function. However, the large sample size of patients obtained
from utilising a national data base may offset some of these
limitations.
The mechanisms responsible for this epidemiological associa-
tion between DM and ARDS are unclear. The effect of DM on
the immune system and inflammatory response is thought to
play a role [19], and perhaps a blunted inflammatory response
effects the development of organ dysfunction in sepsis. Possi-
ble mechanisms of protection in patients with DM may be
impaired neutrophil function or altered neutrophil-endothelial
interactions [20,21]. Obtaining data on specific inflammatory
markers that may play a role in the differences in response to
an infectious insult may clarify the association as well.
Hyperglycaemia may be another factor that influences the
development of ARDS. In our previous prospective study,
there was a trend towards a lower incidence of ARDS in
hyperglycemic patients with no DM; however, this was based
on admission glucose values. This effect may be better under-
stood if haemoglobin A1C levels were available as a marker of
previous glycaemic control, in addition to serial glucose levels
during the patient's stay in the ICU. Another possible explana-
tion for the association between DM and the risk of ARDS may
relate to increased medical care among patients with DM.
Patients with DM may be hospitalised earlier than those with
no DM in the course of their illness because they learn to be
aware of specific signs of infection. Information on timing of
presentation and onset of symptoms, however, may be difficult
to obtain in many patients.
Pharmacological aspects of DM care may also influence the
development of organ dysfunction, because many medica-
tions administered to patients with DM, including insulin and
thiazolidinediones (TZDs), are known to have anti-inflamma-
tory effects in addition to lowering blood glucose. Although the
role of intensive insulin therapy in patients with severe sepsis
remains uncertain, insulin may have other beneficial effects in
this patient population. A key feature of ARDS is the systemic
production of pro-inflammatory mediators and cytokines, such
as tumour necrosis factor (TNF) , interleukin (IL) 1, IL-6 and
IL-8, which have been found in the bronchoalveolar lavage
fluid and plasma of patients with ARDS; and elevated concen-
trations have been associated with an unfavourable outcome
[22-24]. A critical mediator of this inflammatory cascade is the
transcriptional regulatory factor nuclear factor (NF) B, which
may be suppressed by insulin administration. Insulin adminis-
tration to animals challenged with lipopolysaccharide inhibits
TNF production in a dose-dependent manner [25] and pre-
vents the development of ALI [26]. Similarly, TZDs may modu-
late the inflammatory response through the peroxisome-
proliferator-activated receptor gamma and at the transcrip-
tional level through inhibition of NF-B activity [27-31]. Further
investigations on the role of insulin and TZDs on the inflamma-
tory response are necessary to identify a possible mechanism
for affecting the development of ALI.
Conclusions
This study confirms previous observations that a history of DM
is associated with a lower incidence of acute respiratory failure
in patients with severe sepsis. The information obtained moves
us a step closer to better understanding the pathogenesis of
sepsis and sepsis-related organ dysfunction, such as ALI.
Identifying conditions that have an effect on the propensity to
develop organ dysfunction in sepsis will allow for the expan-
sion of studies on interventions for this disease. Further pro-
spective data need to be collected in this cohort of patients to
identify the factors that contribute to this protective effect of
DM.
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Key messages
￿  Patients with DM and severe sepsis are less likely to 
develop acute respiratory failure than patients with no 
DM, irrespective of source of infection.
￿  Patients with DM and severe sepsis are more likely to 
develop acute renal failure than patients with no DM.
￿  The decreased frequency of acute respiratory failure in 
patients with DM and severe sepsis did not translate 
into a significant difference in case fatality.